Review of OEPA/COPDAC regimen in pediatric Hodgkin lymphoma; institutional experience from a low middle-income country
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Intensive chemotherapy like OEPA/COPDAC shows high survival rates for pediatric Hodgkin lymphoma (HL) in low-resource settings. However, frequent toxicities and hospitalizations necessitate improved supportive care.
Area Of Science
- Pediatric Oncology
- Hematology
- Clinical Research
Background
- Pediatric Hodgkin lymphoma (HL) treatment increasingly uses response-adapted protocols.
- Minimizing radiotherapy and using intensive chemotherapy (OEPA/COPDAC) are key strategies.
- Resource-limited settings face unique challenges in implementing advanced protocols.
Purpose Of The Study
- To evaluate treatment outcomes and toxicities of OEPA/COPDAC chemotherapy in pediatric HL patients.
- To assess the feasibility of response-adapted protocols in a low-resource country.
- To analyze survival rates and adverse events associated with this intensive regimen.
Main Methods
- Retrospective review of 20 pediatric HL patients treated between 2015-2019.
- Utilized the Euronet PHL-C1 protocol with OEPA/COPDAC chemotherapy.
- Radiotherapy was reserved for inadequate interim responses.
Main Results
- 65% of patients achieved complete remission after OEPA induction, avoiding radiotherapy.
- High rates of toxicity were observed, including gastrointestinal symptoms and febrile neutropenia.
- Overall survival was 95% and event-free survival was 85%, despite frequent hospitalizations.
Conclusions
- OEPA/COPDAC demonstrates high survival rates for advanced pediatric HL in low-resource settings.
- Substantial toxicity and hospitalization rates highlight the need for enhanced supportive care.
- Further large-scale, long-term studies are warranted to refine treatment strategies.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...